Core Viewpoint - The FDA has approved Bayer's oral androgen receptor inhibitor Nubeqa™ (darolutamide) for use in combination with androgen deprivation therapy (ADT) for metastatic castration-resistant prostate cancer [1] Group 1 - Bayer announced the FDA approval on June 3 [1] - Nubeqa™ is specifically indicated for patients with metastatic castration-resistant prostate cancer [1]